Market Closed -
Nasdaq
04:00:00 2024-05-07 pm EDT
|
5-day change
|
1st Jan Change
|
3.02
USD
|
+0.67%
|
|
+7.47%
|
-5.03%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
296.3
|
57.92
|
30.24
|
25.17
|
24.35
|
-
|
-
|
Enterprise Value (EV)
1 |
296.3
|
57.92
|
30.24
|
25.17
|
24.35
|
24.35
|
24.35
|
P/E ratio
|
-38.4
x
|
-1.9
x
|
-0.97
x
|
-0.76
x
|
-1.07
x
|
-1.5
x
|
-3.47
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,764
x
|
252
x
|
19.9
x
|
12.3
x
|
2.76
x
|
2.82
x
|
0.86
x
|
EV / Revenue
|
1,764
x
|
252
x
|
19.9
x
|
12.3
x
|
2.76
x
|
2.82
x
|
0.86
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-0.58
x
|
-0.54
x
|
-0.6
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-174%
|
-185%
|
-167%
|
Price to Book
|
-
|
-
|
0.51
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
8,297
|
8,357
|
8,376
|
7,915
|
8,116
|
-
|
-
|
Reference price
2 |
35.71
|
6.930
|
3.610
|
3.180
|
3.000
|
3.000
|
3.000
|
Announcement Date
|
3/9/21
|
3/10/22
|
3/1/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.168
|
0.23
|
1.523
|
2.051
|
8.81
|
8.639
|
28.27
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.816
|
-26.3
|
-31.35
|
-32.04
|
-36.61
|
-36.78
|
-41.69
|
-29.08
|
Operating Margin
|
-
|
-15,656.55%
|
-13,629.13%
|
-2,103.74%
|
-1,785.18%
|
-417.46%
|
-482.62%
|
-102.86%
|
Earnings before Tax (EBT)
1 |
-
|
-19.64
|
-31.07
|
-31.08
|
-34.06
|
-35.38
|
-39.86
|
-27.4
|
Net income
1 |
-
|
-6.314
|
-30.43
|
-31.06
|
-34.03
|
-35.38
|
-39.86
|
-27.4
|
Net margin
|
-
|
-3,758.33%
|
-13,230.43%
|
-2,039.53%
|
-1,659.39%
|
-401.64%
|
-461.43%
|
-96.94%
|
EPS
2 |
-
|
-0.9300
|
-3.650
|
-3.710
|
-4.180
|
-2.812
|
-2.006
|
-0.8650
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
-42.34
|
-45.09
|
-40.73
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-480.56%
|
-521.96%
|
-144.08%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/1/20
|
3/9/21
|
3/10/22
|
3/1/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
0.22
|
0.111
|
-
|
0.497
|
0.512
|
0.691
|
0.527
|
0.007
|
0.826
|
0.3026
|
8.303
|
0.1026
|
0.3026
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-7.497
|
-6.569
|
-7.731
|
-
|
-7.55
|
-8.835
|
-8.035
|
-9.643
|
-8.932
|
-10
|
-9.869
|
-2.543
|
-11.35
|
-13.02
|
-12.8
|
Operating Margin
|
-
|
-2,985.91%
|
-6,964.86%
|
-
|
-1,519.11%
|
-1,725.59%
|
-1,162.81%
|
-1,829.79%
|
-127,600%
|
-1,211.14%
|
-3,261.34%
|
-30.63%
|
-11,059.84%
|
-4,302.45%
|
-
|
Earnings before Tax (EBT)
1 |
-7.488
|
-6.277
|
-7.72
|
-
|
-7.251
|
-8.26
|
-7.346
|
-8.96
|
-8.3
|
-9.457
|
-9.731
|
-2.407
|
-11.02
|
-12.23
|
-12.8
|
Net income
1 |
-7.488
|
-5.641
|
-7.72
|
-7.844
|
-7.251
|
-8.247
|
-7.346
|
-8.931
|
-8.3
|
-9.457
|
-9.731
|
-2.407
|
-11.02
|
-12.23
|
-12.8
|
Net margin
|
-
|
-2,564.09%
|
-6,954.95%
|
-
|
-1,458.95%
|
-1,610.74%
|
-1,063.1%
|
-1,694.69%
|
-118,571.43%
|
-1,144.92%
|
-3,215.8%
|
-28.99%
|
-10,741.72%
|
-4,040.38%
|
-
|
EPS
2 |
-0.9000
|
-0.6800
|
-0.9200
|
-0.9400
|
-0.8600
|
-0.9800
|
-0.8900
|
-1.090
|
-1.040
|
-1.170
|
-1.176
|
-0.6760
|
-0.6600
|
-0.7240
|
-1.200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/3/21
|
3/10/22
|
5/10/22
|
8/10/22
|
11/14/22
|
3/1/23
|
5/5/23
|
8/9/23
|
11/7/23
|
3/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
-42.3
|
-45.1
|
-40.7
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-7.770
|
-
|
-
|
7.120
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
0.02
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
1.38%
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/1/20
|
3/9/21
|
3/10/22
|
3/1/23
|
3/7/24
|
-
|
-
|
-
|
Average target price
22.5
USD Spread / Average Target +650.00% Consensus |
1st Jan change
|
Capi.
|
---|
| -5.03% | 24.35M | | +21.74% | 46.81B | | -0.97% | 41.37B | | +47.07% | 41.29B | | -3.52% | 28.87B | | +11.12% | 26.06B | | -19.37% | 19.13B | | +31.18% | 12.39B | | -0.04% | 12.08B | | +0.39% | 11.96B |
Other Biotechnology & Medical Research
|